KEYNOTE-348: This phase I trial is combining a new drug (blinatumomab) with a commonly used immunotherapy drug (pembrolizumab) for the treatment of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL)A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Exclusion

• Richter's transformation (DLBCL arising in the setting of prior chronic lymphocytic leukemia) or primary mediastinal B cell lymphoma (PMBCL)
• History or presence of clinically relevant central nervous system pathology such as epilepsy, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.
• Has a diagnosis of immunodeficiency or has received systemic steroid therapy (in excess of 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of protocol specified therapy.
• Has undergone prior allogeneic HSCT:
• within the last 5 years OR
• greater than 5 years ago but has active graft versus host disease (GvHD) requiring systemic treatment.
• Has received autologous HSCT within 6 weeks prior to start of treatment.

Other Exclusion Criteria May Apply.